CareDx, Inc (NASDAQ:CDNA) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's CareDx Second Quarter 2025 Earnings Call.
Caredx Inc. (CDNA)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 2,100,157 | $41,037,064 | -11% | 0.3% |
| 2. | Hood River Capital Management David Swank | 1,765,981 | $34,507,269 | +12% | 0.48% |
| 3. | Ophir Asset Management Steven Ng And Andrew Mitchell | 1,892,994 | $24,343,903 | +17% | 3.87% |
| 4. | Renaissance Technologies Jim Simons | 1,155,698 | $22,582,339 | -7% | 0.03% |
| 5. | Citadel Investment Group Ken Griffin | 790,667 | $15,449,633 | -1% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.34 | 5,000 | $211,693.50 | 5,000 | 2021-11-24 | Filing | |
| $47.62 | 600 | $28,572.00 | 2,855 | 2021-11-05 | Filing | |
| $9.42 | 10,136 | $95,481.12 | 965,894 | 2018-04-26 | Filing | |
| $4.00 | 1,278 | $5,112.00 | 40,529 | 2017-10-05 | Filing | |
| $4.00 | 9,364 | $37,456.00 | 928,768 | 2017-10-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.79 | 2,688 | $34,380.60 | 112,930 | 2025-08-05 | Filing | |
| $18.58 | 10,000 | $185,831.00 | 308,846 | 2025-07-07 | Filing | |
| $19.16 | 10,570 | $202,565.59 | 38,994 | 2025-06-18 | Filing | |
| $19.24 | 10,000 | $192,420.00 | 318,846 | 2025-06-17 | Filing | |
| $19.90 | 19,391 | $385,917.74 | 53,979 | 2025-06-11 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,910,571 | $95,952,557 | 0% | |
| 2. | 4,657,919 | $91,015,739 | 0% | |
| 3. | 2,543,419 | $49,698,407 | 0.01% | |
| 4. | 2,435,657 | $47,592,738 | 0.13% | |
| 5. | 2,180,145 | $42,600,033 | 0% |
News See All
CareDx, Inc (NASDAQ:CDNA) Q1 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's CareDx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only-mode.
CareDx, Inc (NASDAQ:CDNA) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, everyone. Welcome to the CareDx, Inc. Fourth Quarter and Fiscal Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only-mode.
CareDx (CDNA) Traded Down Due to Disappointing Quarterly Results
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S.
Here’s Why CareDx (CDNA) Traded Lower in Q4
Baron Funds, an investment management company, released its “Baron Discovery Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here.
Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA)
Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S.
Accelerated Testing Volume Lifted CareDx (CDNA) in Q3
Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
CareDx, Inc (NASDAQ:CDNA) Q3 2024 Earnings Call Transcript
Operator: Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
CareDx (CDNA) Surged Due to Positive Testing Volume Growth
Baron Funds, an investment management company, released its “Baron Discovery Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Best Organ Transplant and Diagnosis Stocks To Buy Now
In the dynamic landscape of healthcare, the importance of organ transplantation cannot be overstated.